吡嗪酰胺耐药对初治菌阳肺结核复发的影响

发布时间：2018-06-22 00:44

本文选题：肺结核 + 吡嗪酰胺　；参考：《实用医学杂志》2016年13期

【摘要】：目的:探讨吡嗪酰胺(PZA)耐药对初治菌阳肺结核复发的影响。方法:对2012年1月至2013年8月在我院完成诊治且随访2年的150例初治菌阳肺结核患者进行回顾性分析。根据患者治疗前PZA的药敏试验结果分为PZA敏感组(114例)和PZA耐药组(36例)。结果:(1)疗程结束时,敏感组和耐药组的治愈率分别为98.25%和88.89%(P=0.044),病灶吸收率分别为99.12%和94.44%(P=0.143),空洞缩小率分别为89.01%和70.37%(P=0.039)。(2)敏感组和耐药组停药后2年内复发率分别为3.57%和6.25%(P=0.867)。结论 :PZA耐药对初治菌阳肺结核的治疗效果有一定影响,其耐药者与敏感者相比具有更低的空洞缩小率,但停药后2年内复发率尚未见明显差异。
[Abstract]:Objective: to investigate the effect of pyrazinamide (PZA) resistance on the recurrence of primary positive pulmonary tuberculosis. Methods: a retrospective analysis was performed on 150 patients with newly diagnosed positive pulmonary tuberculosis who were treated in our hospital from January 2012 to August 2013 and followed up for 2 years. According to the results of PZA drug sensitivity test before treatment, patients were divided into PZA sensitive group (114 cases) and PZA resistant group (36 cases). Results: (1) at the end of the treatment, the cure rate was 98.25% in the sensitive group and 88.89% in the resistant group (P0. 044), the lesion absorptivity was 99. 12% and 94. 44% (P0. 143), the cavity reduction rate was 89. 01% and 70. 37% (P0. 039). (2) and the relapse rate in the resistant group was 3. 57% and 6. 25% (P0. 867) respectively. Conclusion the drug resistance of PZA has a certain effect on the treatment of primary positive pulmonary tuberculosis. The drug resistant patients have lower cavity reduction rate than the sensitive patients, but there is no significant difference in the recurrence rate within 2 years after the withdrawal of the drug.
【作者单位】：广州医科大学;江西省赣南医学院第一附属医院;广州市胸科医院结核内科呼吸疾病国家重点实验室;
【基金】：国家自然科学基金(编号:81572037) 广东省科技计划课题(编号:2013-137-115) 广州市科信局计划课题(编号:155700012)
【分类号】：R521

【相似文献】